US vaccine maker Novavax mentioned on Monday that new knowledge from Novavax’s ongoing analysis on its up to date XBB.1.5 Covid-19 vaccine in contributors who beforehand acquired an mRNA vaccine confirmed strong neutralizing antibody titers for the XBB.1.5 subvariant in addition to for the presently circulating JN.1 subvariant.
The knowledge additionally confirmed that the vaccine’s security and reactogenicity profile was in line with its prototype vaccine (NVX-CoV2373).
Source: www.anews.com.tr
